Symbol
| CYP2C9
| contributors: mct - updated : 17-11-2021
|
HGNC name
| cytochrome P450, family 2, subfamily C, polypeptide 9
|
HGNC id
| 2623
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --low
|  
|
in multiple cohorts of human esophageal squamous cell carcinoma (ESCC)  | |
Susceptibility
|
to adverse drug reactions/toxicities when drugs extensively metabolized by CYP2C9 to warfarin resistance to variation of the metabolism of warfarin and other drugs |
Variant & Polymorphism
SNP
, other
| variability interindividual and ethnic |
|
increasing the warfarin resistance |
|
CYP2C9 variants have significantly decreased function and have the potential to impact the metabolism of warfarin and other drugs  |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | digestive | oesophagus |  |
Overexpression of CYP2C9 reduced the invasion and migration of esophageal squamous cell carcinoma (ESCC) cells |
| | | |